Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.

Publication date: Oct 22, 2019

The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12- and 18-month recurrence-free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19-2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence.

Yokota, K., Uchi, H., Uhara, H., Yoshikawa, S., Takenouchi, T., Inozume, T., Ozawa, K., Ihn, H., Fujisawa, Y., Qureshi, A., Pril, de, Otsuka, Y., Weber, J., and Yamazaki, N. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study. 24525. 2019 J Dermatol.

Concepts Keywords
Adjuvant Therapy Ipilimumab Japanese melanoma
Confidence Interval Adjuvant drug therapy
Ipilimumab Adjuvant therapy
Japanese Clinical medicine
Melanoma Bristol-Myers Squibb
Multinational Cancer treatments
Resection Monoclonal antibodies
Subgroup Antineoplastic drugs
Breakthrough therapy
Nivolumab
Melanoma
Ipilimumab
Adjuvant therapy

Semantics

Type Source Name
disease MESH recurrence
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *